RJA
LLY icon

Raymond James & Associates’s Eli Lilly LLY Stock Holding History

Raymond James & Associates’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$219K Buy
+300
New +$270K ﹤0.01% 3589
2023
Q3 		– Sell
-5,500
Closed -$2.31M – 3871
2023
Q2 		$2.31M Sell
5,500
-5,500
-50% -$2.31M ﹤0.01% 1969
2023
Q1 		$3.85M Buy
11,000
+5,500
+100% +$1.85M ﹤0.01% 1650
2022
Q4 		$298K Buy
+5,500
New +$1.95M ﹤0.01% 3220

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Raymond James & Associates's LLY Position: Q3 2024 in Review

Raymond James & Associates increased its Eli Lilly (LLY) stake by 7.3% in Q3 2024, buying an estimated $67.7M and bringing the position to 1,099,584 shares worth $974M. The position accounts for 0.59% of the portfolio, ranked #26.

Raymond James & Associates first reported a position in LLY in Q2 2013 and has held it in 46 quarters since. 3,657 funds tracked by Wall St. Rank hold LLY as of Q3 2024.

  • Raymond James & Associates held 1,099,584 shares of Eli Lilly worth $974M as of Q3 2024.
  • Raymond James & Associates bought 75,280 Eli Lilly shares in Q3 2024, an estimated $67.7M.
  • Eli Lilly made up 0.59% of Raymond James & Associates's portfolio in Q3 2024, its #26 holding.
  • Raymond James & Associates first reported a position in Eli Lilly in Q2 2013 and has held it in 46 quarters since.
  • 3,657 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.